Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated-as any anticoagulant-with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.


  • Eikelboom, John
  • Kozek-Langenecker, S
  • Exadaktylos, A
  • Batorova, A
  • Boda, Z
  • Christory, F
  • Gornik, I
  • Kėkštas, G
  • Kher, A
  • Komadina, R
  • Koval, O
  • Mitic, G
  • Novikova, T
  • Pazvanska, E
  • Ratobilska, S
  • Sütt, J
  • Winder, A
  • Zateyshchikov, D

publication date

  • April 2018